High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair ...
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with ...
QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...
Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide® Once-daily Ultibro® Breezhaler® reduced exacerbations (flare ups) by 31% ...
Results confirm non-inferiority of Onbrez® Breezhaler® (indacaterol) in lung function compared to Seretide®* (salmeterol/fluticasone) in the studied population In ...
In a few years, patients with chronic breathing problems will puff on an Internet-connected inhaler that instantly sends data about how often the device is used to the medicine provider and doctors ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Enerzair Breezhaler, the first triple-combination asthma therapy that ...
Propeller Health is teaming up with Novartis to develop a custom add-on sensor for the Big Pharma’s Breezhaler inhaler. The tie-up marks Propeller’s fifth pharma partnership and its third with a major ...
Novartis and UK group Vectura will be celebrating news that regulators in Europe and Japan have issued green lights for the dual bronchodilator Ultibro Breezhaler for the treatment of COPD, a ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
Basel, April 25, 2014 - Novartis announced today top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease (COPD), which met its primary objective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results